Peregrine Officially End Late-Stage Development of Bavituximab
The biotech continues to look for alternative data that could resurrect its lead product after a slew of failures.
You may also be interested in...
Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.